- Ova-Mit is indicated for the treatment of ovulatory failure in women desiring pregnancy. Good levels of endogenous estrogen provide a favorable prognosis for ovulatory response induced by Ova-Mit. Therapy is ineffective in patients with primary pituitary or primary ovarian failure.
Dosage:
The recommended dose for the first course of Ova-Mit is 50 mg (1 tablet) daily for 5 days. Therapy may be started at any time in the patient who has had no recent uterine bleeding. If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs before therapy, the regimen of 50 mg daily for 5 days should be started on or about the fifth day of the cycle.
If ovulation appears not to have occurred after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one. Increase of the dosage or duration of therapy beyond 100 mg/day for 5 days should not be undertaken.
The majority of patients who are going to respond will respond to the first course of therapy, and 3 courses should constitute an adequate therapeutic trial. If ovulatory menses have not yet occurred, the diagnosis should be re-evaluated. Treatment beyond this is not recommended in the patient who does not exhibit evidence of ovulation.
Administration:
Swallow the tablet whole with a full glass of water.
Do not chew or crush the tablet.
Can be taken with or without food.
Missed Dose:
If a dose is missed, take it as soon as remembered, unless it's almost time for the next dose.
Do not take two doses at the same time to make up for a missed dose.
Storage:
Store in a cool, dry place away from direct sunlight.
Keep out of reach of children.
Malaysia
